SCHEMBL258020

SCHEMBL258020

CCCCOc1cccc(Oc2ccc(C)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.62
FFAR4 Q5NUL3 1/20 0.53
DRD2 P14416 3/20 0.53
DRD4 P21917 3/20 0.53
DRD3 P35462 3/20 0.53
ACACB O00763 1/20 0.52
ACACA Q13085 1/20 0.52
TSHR P16473 1/20 0.50
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HTT P42858 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PLA2G4B P0C869 1/20 0.47
GPBAR1 Q8TDU6 1/20 0.47
CYSLTR2 Q9NS75 1/20 0.47
CYSLTR1 Q9Y271 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9487103 0.91 LTA4H (0.68) LTA4HACACBACACATSHRKDM4E
SCHEMBL15474284 0.89 FFAR4 (0.56) LTA4HFFAR4DRD2DRD4DRD3
SCHEMBL12967962 0.89 LTA4H (0.79) LTA4HACACBACACATSHRKDM4E
SCHEMBL8736875 0.86 LTA4H (0.60) LTA4HFFAR4DRD2DRD4DRD3
SCHEMBL8595300 0.85 LTA4H (0.70) LTA4HDRD2DRD4DRD3ALDH1A1
SCHEMBL4397448 0.85 TSHR (0.63) LTA4HTSHRSMN1; SMN2PLA2G4BGPBAR1
SCHEMBL12260869 0.85 LTA4H (0.61) LTA4HACACBACACATSHRKDM4E
SCHEMBL10238690 0.85 LTA4H (0.61) LTA4HACACBACACATSHRKDM4E
SCHEMBL17905721 0.84 LTA4H (0.77) LTA4HTSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL920058 0.83 LTA4H (0.59) LTA4HACACBACACATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624239-B2 Protein kinase inhibitors PHARMASCIENCE INC. (CA) 2017-04-18 US disclosed
US-20140045833-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2014-02-13 US disclosed
WO-2012135944-A9 PROTEIN KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2014-01-09 WO disclosed
EP-2404607-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2012-01-11 EP disclosed
EP-2399585-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2011-12-28 EP disclosed
EP-2073816-B1 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC (US) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045833-A1 Protein Kinase Inhibitors LCK, BTK, TEC LTA4H 4288/4885FFAR4 4114/4885DRD2 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.